Welcome to our dedicated page for Greenwich LifeSciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich LifeSciences stock.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company dedicated to the development of groundbreaking immunotherapies aimed at preventing breast cancer recurrences. The company's flagship product, GP2, is an immunotherapy designed to stimulate the body's immune system to target and eliminate HER2/neu-expressing cancer cells, particularly in patients who have already undergone surgery for breast cancer.
GP2 leverages the HER2/neu transmembrane peptide to elicit a targeted immune response, providing a promising approach to cancer treatment. Another significant component of their pipeline is the GM-CSF Immunoadjuvant, which has shown potential in enhancing monocyte and neutrophil cytotoxicity against melanoma tumor cells, as well as boosting activity-dependent cellular cytotoxicity against targets coated with anti-ganglioside antibodies.
The company’s ongoing clinical trials are a testament to its commitment to innovation and excellence in cancer treatment. These trials are being conducted in collaboration with a steering committee comprising esteemed members from various medical institutions, ensuring rigorous oversight and adherence to the highest standards of clinical research.
Greenwich LifeSciences places a strong emphasis on advancing cancer immunotherapy to selectively stimulate an individual's immune system to attack cancer cells, thereby inhibiting the spread of the disease. Their work not only focuses on breast cancer but extends to other cancer types, showcasing a broad potential for impact in oncology.
With a robust pipeline, strategic partnerships, and a clear focus on unmet medical needs, Greenwich LifeSciences is poised to be a leader in the biopharmaceutical industry. Investors and stakeholders can stay updated on the latest developments and company performance through regular news updates and reports.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has appointed Christine Fischette, Ph.D., as Vice President of Business Development. Dr. Fischette aims to expand the company’s pipeline and pursue strategic partnerships for its immunotherapy product, GP2, which has shown promising results in preventing breast cancer recurrences. The final safety data from a Phase IIb trial will be presented at the upcoming ASCO conference, which, if positive, could enhance GP2's market appeal. CEO Snehal Patel emphasized that Dr. Fischette's experience will be vital as they target new breast cancer markets.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the publication of a second poster detailing the GP2 Phase III clinical trial design at the 2021 AACR Annual Meeting. Led by Dr. Mothaffar F. Rimawi, the trial aims to treat up to 500 patients to evaluate GP2 as an immunotherapy to prevent breast cancer recurrences post-surgery. The trial is based on promising Phase IIb results showing 100% invasive Disease-Free Survival (iDFS) after 5 years. An interim analysis is planned, and the trial will explore expanding the treatment for various HLA types.
Greenwich LifeSciences (Nasdaq: GLSI) presented final immune response data from a 5-year Phase IIb clinical trial of GP2, an immunotherapy for preventing breast cancer recurrences, at the 2021 AACR Annual Meeting. The study showed that those completing the GP2 treatment had a 0% recurrence rate over five years. Significant peak immunity was achieved after 6 months of GP2 treatment, with positive immune responses observed in both HER2 3+ and HER2 1-2+ populations. These results suggest potential broader applications for GP2 in treating other HER2-related cancers.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced the final 5-year immune response data from its Phase IIb clinical trial at the 2021 AACR Annual Meeting. This data is crucial for developing dosing strategies for GP2, an immunotherapy aimed at preventing breast cancer recurrences. The AACR published the data abstract on April 9, with a poster to be released on April 10. Additional updates on Phase III trial design are expected the week of April 12, and safety data presentations are scheduled for the ASCO conference on June 4.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced CEO Snehal Patel's participation in the Benzinga Biotech Small-Cap Conference on March 24, 2021. He will be involved in a 30-minute immunotherapy oncology panel at 10:25 am EST and a live 15-minute presentation at 12:35 pm EST, followed by a Q&A session. The company is focused on developing GP2, an immunotherapy intended to prevent breast cancer recurrences in previously treated patients. The Phase IIb trial showed promising results with no recurrences after five years.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced acceptance of two abstracts for presentation at the virtual AACR Annual Meeting 2021, scheduled for April 10-15. The first abstract features five-year immune response data from the Phase IIb clinical trial, critical for finalizing Phase III trial designs. CEO Snehal Patel noted that GP2 manufacturing is on track for completion in mid-2021, with patient enrollment in Phase III expected by late 2021. The company aims to assess HER2/neu responses for potential combined therapies.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that CEO Snehal Patel will be interviewed live on Benzinga’s Power Hour on March 11, 2021. During the 15-20 minute segment, Mr. Patel will discuss the successful Phase IIb clinical trial of GP2, an immunotherapy with 0% breast cancer recurrences observed over 5 years. He will also outline plans for a Phase III trial and key upcoming milestones. GP2 targets HER2/neu positivity, aiming to prevent breast cancer recurrences in post-surgery patients. The company has reported no serious adverse events in 138 treated patients thus far.
Greenwich LifeSciences (Nasdaq: GLSI) has appointed Jaye Thompson, PhD, as Vice President of Clinical and Regulatory Affairs to spearhead the GP2 Phase III clinical trial aimed at preventing breast cancer recurrences. Dr. Thompson emphasizes the urgency for effective treatments for the 3 million U.S. breast cancer survivors. Notably, GP2's Phase IIb trial reported no recurrences over five years in treated patients. The company aims to replicate these promising results in the upcoming trial, with plans to engage multiple sites and optimize resource allocation for clinical and regulatory proceedings.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced CEO Snehal Patel's participation in several virtual investor conferences in March 2021. Notable events include the H.C. Wainwright Global Life Sciences Conference on March 9, the Landmark Health Innovations Conference on March 11, and the BIO-Europe Spring from March 22-25. The company also plans to present at the Benzinga Biotech Small-Cap Conference on March 25. Greenwich LifeSciences focuses on GP2, an immunotherapy aimed at preventing breast cancer recurrences, reporting no recurrences in a recent clinical trial with 138 patients.
Greenwich LifeSciences (Nasdaq: GLSI) announced acceptance of two abstracts for presentation at the AACR Annual Meeting 2021. The presentations will highlight GP2, an immunotherapy designed to prevent breast cancer recurrences. The first abstract discusses the final 5-year immune response analysis from the Phase IIb trial, which showed a 0% recurrence rate in HER2/neu 3+ patients. The second abstract outlines the design of the upcoming Phase III clinical trial, aiming for FDA conditional marketing approval based on interim results.
FAQ
What is the current stock price of Greenwich LifeSciences (GLSI)?
What is the market cap of Greenwich LifeSciences (GLSI)?
What is Greenwich LifeSciences, Inc.?
What is GP2?
What does the GM-CSF Immunoadjuvant do?
What types of cancer is Greenwich LifeSciences targeting?
Who oversees the clinical trials at Greenwich LifeSciences?
What is the significance of HER2/neu in cancer treatment?
Are there any ongoing clinical trials?
How can investors stay updated on the company?
What makes Greenwich LifeSciences' approach unique?
Where can I find more information about Greenwich LifeSciences?
